Howard Adrienne N, Bridges Kathleen A, Meyn Raymond E, Chandra Joya
Department of Pediatrics Research, The University of Texas M D Anderson Cancer Center, Box 853, 1515 Holcombe Blvd, Houston, TX 77030, USA.
Cancer Chemother Pharmacol. 2009 Dec;65(1):41-54. doi: 10.1007/s00280-009-1001-1. Epub 2009 Apr 29.
This study assessed the role of oxidative stress and loss of glutathione in ABT-737-induced apoptosis.
Jurkat human acute lymphocytic leukemia cells and HeLa cells transfected with a tet-regulated Bcl-2 expression system were treated with ABT-737 or its less active stereoisomer. GSH concentrations, intracellular reactive oxygen species (ROS), caspase activation and apoptotic DNA fragmentation were measured.
ABT-737 induced oxidative stress through decreased GSH and increased intracellular hydrogen peroxide and superoxide levels. Apoptotic DNA fragmentation and caspase activation were the consequences of this oxidative stress. Combining ABT-737 with ROS-inducing agents such as adaphostin or etoposide enhanced cell death.
These results demonstrate that inhibition of Bcl-2 causes a loss of GSH, an increase in ROS, caspase activation and subsequent apoptosis. Clinically, redox alterations as a consequence of Bcl-2 inhibition by ABT-737 should be considered in devising combination therapies with this novel agent or its derivatives.
本研究评估氧化应激和谷胱甘肽缺失在ABT - 737诱导的细胞凋亡中的作用。
用ABT - 737或其活性较低的立体异构体处理Jurkat人急性淋巴细胞白血病细胞和转染了四环素调控的Bcl - 2表达系统的HeLa细胞。测定谷胱甘肽浓度、细胞内活性氧(ROS)、半胱天冬酶激活情况及凋亡性DNA片段化。
ABT - 737通过降低谷胱甘肽水平及提高细胞内过氧化氢和超氧化物水平诱导氧化应激。凋亡性DNA片段化和半胱天冬酶激活是这种氧化应激的结果。将ABT - 737与ROS诱导剂如阿多福司汀或依托泊苷联合使用可增强细胞死亡。
这些结果表明,抑制Bcl - 2会导致谷胱甘肽缺失、ROS增加、半胱天冬酶激活及随后的细胞凋亡。临床上,在设计使用这种新型药物或其衍生物的联合治疗方案时,应考虑ABT - 737抑制Bcl - 2所导致的氧化还原改变。